Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Cardiff Oncology Inc (CRDF)

Cardiff Oncology Inc (CRDF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 GlobeNewswire - Mon Dec 8, 3:05PM CST

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.95 (-6.94%)
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference GlobeNewswire - Mon Dec 8, 6:00AM CST

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.95 (-6.94%)
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Mon Nov 24, 6:00AM CST

SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.95 (-6.94%)
Cardiff Oncology: Q3 Earnings Snapshot AP - Thu Nov 6, 3:33PM CST

Cardiff Oncology: Q3 Earnings Snapshot

CRDF : 2.95 (-6.94%)
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update GlobeNewswire - Thu Nov 6, 3:05PM CST

– Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects...

CRDF : 2.95 (-6.94%)
Cardiff Oncology to Participate in Two Upcoming Investor Conferences GlobeNewswire - Tue Nov 4, 3:01PM CST

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.95 (-6.94%)
Cardiff Oncology to Participate in Two Upcoming Investor Conferences GlobeNewswire - Thu Oct 2, 3:05PM CDT

SAN DIEGO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.95 (-6.94%)
Cardiff Oncology to Participate in Three Upcoming Investor Conferences GlobeNewswire - Thu Aug 28, 3:05PM CDT

SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers,...

CRDF : 2.95 (-6.94%)
Cardiff Oncology: Q2 Earnings Snapshot AP - Tue Jul 29, 3:23PM CDT

Cardiff Oncology: Q2 Earnings Snapshot

CRDF : 2.95 (-6.94%)
Cardiff Oncology Announces Positive Data from Ongoing Randomized Phase 2 First-line RAS-mutated mCRC Clinical Trial (CRDF-004) GlobeNewswire - Tue Jul 29, 3:07PM CDT

– Trial demonstrates 49% confirmed ORR in the 30mg onvansertib dose arm versus 30% confirmed ORR in the control arm in intent-to-treat population (N=110) – – Early PFS data show a trend favoring...

CRDF : 2.95 (-6.94%)

Barchart Exclusives

This Dividend-Yielding Gold Stock Is Up 184% in 2025. Should You Bet on Higher Gold Prices in 2026? Barchart - Mon Dec 29, 6:30PM CST
Barrick Gold is up big as gold prices continue to hit new records. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot